AccuPulse Medical Honored as 'Best Innovative Medical Device Company of the Year' at the 9th Healthcare Investment Excellence Awards

The 9th Healthcare Investment Excellence Awards

On July 30, 2025, Haoyue Capital officially released the "9th Healthcare Investment Excellence List."”, AccuPulsePulseMedicalAccuPulse Medical Technology Co.Ltd"Best Company for Annual Innovative Medical Devices" Award。

The "Healthcare Investment Excellence Awards" crafted by Haoyue Capital has entered its ninth year, continuously upholding "fairness, impartiality, openness, and neutrality" as the cornerstone of evaluation. It comprehensively analyzes the overall strength of investment institutions across multiple dimensions, including activity in the healthcare industry, transaction volume, return performance, and post-investment support. The list also focuses on five core sectors: innovative pharmaceuticals, innovative medical devices, IVD and life sciences, health services and smart healthcare, and biotechnology. It selects benchmark enterprises and investment forces of the year, aiming to establish a value benchmark for the industry and drive shared prosperity within the ecosystem.

Since its establishment in 2020, AccuPulse Medical has developed multiple product pipelines based on new technologies such as pulsed field ablation (PFA) and innovative 3D mapping. In April 2025, AccuPulse’s self-developed AccuQuest® transseptal puncture system, AccuQuest® transseptal puncture needle, and cardiac pulse ablation system (composed of the AccuPulse® single-use cardiac pulsed field ablation catheter and AccuBlator® cardiac pulsed field ablation generator) were successively approved for marketing by the National Medical Products Administration (NMPA).

Riding Through Cycles, Warm Currents Surge. China's healthcare and life sciences industry ushers in a structural recovery amidst profound transformation in 2025. The first half of the year saw steadily increasing financing activity across all sectors, with several landmark major deals being finalized. A series of "hardcore" innovation cases not only injected confidence into the market but also marked the official entry of China’s medical innovation into a new phase characterized by high quality, internationalization, and value-driven growth.